Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Edith A. Perez, Amylou Dueck, Ann E. McCullough, Monica M. Reinholz, Kathleen S. Tenner, Nancy E. Davidson, Julie Gralow, Lyndsay N. Harris, Leila A. Kutteh, David W. Hillman, Robert Brian Jenkins, Beiyun Chen

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from the HER2-positive breast cancer adjuvant trial N9831, we compared eligibility for patients who met both criteria, and disease-free survival (DFS) was assessed by Cox proportional hazards regression. The number of patients in the N9831 trial retrospectively eligible for trastuzumab therapy was decreased when ASCO/CAP criteria vs FDA criteria were applied to immunohistochemistry and/or fluorescence in situ hybridization results (107 [3.7%] of 2904 patients with immunohistochemistry results, 37 [1.3%] of 2809 patients with fluorescence in situ hybridization results, and 47 [1.7%] of 2809 patients with both results). Improvement in DFS was similar among patients treated with trastuzumab under either set of criteria (concurrent trastuzumab and chemotherapy compared with chemotherapy alone: by ASCO/CAP criteria, hazard ratio of DFS = 0.59, 95% confidence interval = 0.48 to 0.73; by FDA criteria but not ASCO/CAP criteria, hazard ratio = 0.60, 95% confidence interval = 0.12 to 3.13; number needed to treat to prevent one additional DFS event at 5 years: 10 and 11.2 patients, respectively). Following the 2007 ASCO/CAP criteria for HER2 positivity would negate the option of potentially life-saving trastuzumab therapy for a small but meaningful group of patients. We recommend using FDA-approved HER2 criteria for therapeutic decision making.

Original languageEnglish (US)
Pages (from-to)159-162
Number of pages4
JournalJournal of the National Cancer Institute
Volume104
Issue number2
DOIs
StatePublished - Jan 18 2012

Fingerprint

Medical Oncology
United States Food and Drug Administration
Disease-Free Survival
Fluorescence In Situ Hybridization
Immunohistochemistry
Confidence Intervals
Drug Therapy
Numbers Needed To Treat
Pathologists
Trastuzumab
Uncertainty
Decision Making
Therapeutics
Joints
Guidelines
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. / Perez, Edith A.; Dueck, Amylou; McCullough, Ann E.; Reinholz, Monica M.; Tenner, Kathleen S.; Davidson, Nancy E.; Gralow, Julie; Harris, Lyndsay N.; Kutteh, Leila A.; Hillman, David W.; Jenkins, Robert Brian; Chen, Beiyun.

In: Journal of the National Cancer Institute, Vol. 104, No. 2, 18.01.2012, p. 159-162.

Research output: Contribution to journalArticle

Perez, EA, Dueck, A, McCullough, AE, Reinholz, MM, Tenner, KS, Davidson, NE, Gralow, J, Harris, LN, Kutteh, LA, Hillman, DW, Jenkins, RB & Chen, B 2012, 'Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria', Journal of the National Cancer Institute, vol. 104, no. 2, pp. 159-162. https://doi.org/10.1093/jnci/djr490
Perez, Edith A. ; Dueck, Amylou ; McCullough, Ann E. ; Reinholz, Monica M. ; Tenner, Kathleen S. ; Davidson, Nancy E. ; Gralow, Julie ; Harris, Lyndsay N. ; Kutteh, Leila A. ; Hillman, David W. ; Jenkins, Robert Brian ; Chen, Beiyun. / Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. In: Journal of the National Cancer Institute. 2012 ; Vol. 104, No. 2. pp. 159-162.
@article{8a0ce64b7c004513aff429f60838356d,
title = "Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria",
abstract = "The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from the HER2-positive breast cancer adjuvant trial N9831, we compared eligibility for patients who met both criteria, and disease-free survival (DFS) was assessed by Cox proportional hazards regression. The number of patients in the N9831 trial retrospectively eligible for trastuzumab therapy was decreased when ASCO/CAP criteria vs FDA criteria were applied to immunohistochemistry and/or fluorescence in situ hybridization results (107 [3.7{\%}] of 2904 patients with immunohistochemistry results, 37 [1.3{\%}] of 2809 patients with fluorescence in situ hybridization results, and 47 [1.7{\%}] of 2809 patients with both results). Improvement in DFS was similar among patients treated with trastuzumab under either set of criteria (concurrent trastuzumab and chemotherapy compared with chemotherapy alone: by ASCO/CAP criteria, hazard ratio of DFS = 0.59, 95{\%} confidence interval = 0.48 to 0.73; by FDA criteria but not ASCO/CAP criteria, hazard ratio = 0.60, 95{\%} confidence interval = 0.12 to 3.13; number needed to treat to prevent one additional DFS event at 5 years: 10 and 11.2 patients, respectively). Following the 2007 ASCO/CAP criteria for HER2 positivity would negate the option of potentially life-saving trastuzumab therapy for a small but meaningful group of patients. We recommend using FDA-approved HER2 criteria for therapeutic decision making.",
author = "Perez, {Edith A.} and Amylou Dueck and McCullough, {Ann E.} and Reinholz, {Monica M.} and Tenner, {Kathleen S.} and Davidson, {Nancy E.} and Julie Gralow and Harris, {Lyndsay N.} and Kutteh, {Leila A.} and Hillman, {David W.} and Jenkins, {Robert Brian} and Beiyun Chen",
year = "2012",
month = "1",
day = "18",
doi = "10.1093/jnci/djr490",
language = "English (US)",
volume = "104",
pages = "159--162",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

AU - Perez, Edith A.

AU - Dueck, Amylou

AU - McCullough, Ann E.

AU - Reinholz, Monica M.

AU - Tenner, Kathleen S.

AU - Davidson, Nancy E.

AU - Gralow, Julie

AU - Harris, Lyndsay N.

AU - Kutteh, Leila A.

AU - Hillman, David W.

AU - Jenkins, Robert Brian

AU - Chen, Beiyun

PY - 2012/1/18

Y1 - 2012/1/18

N2 - The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from the HER2-positive breast cancer adjuvant trial N9831, we compared eligibility for patients who met both criteria, and disease-free survival (DFS) was assessed by Cox proportional hazards regression. The number of patients in the N9831 trial retrospectively eligible for trastuzumab therapy was decreased when ASCO/CAP criteria vs FDA criteria were applied to immunohistochemistry and/or fluorescence in situ hybridization results (107 [3.7%] of 2904 patients with immunohistochemistry results, 37 [1.3%] of 2809 patients with fluorescence in situ hybridization results, and 47 [1.7%] of 2809 patients with both results). Improvement in DFS was similar among patients treated with trastuzumab under either set of criteria (concurrent trastuzumab and chemotherapy compared with chemotherapy alone: by ASCO/CAP criteria, hazard ratio of DFS = 0.59, 95% confidence interval = 0.48 to 0.73; by FDA criteria but not ASCO/CAP criteria, hazard ratio = 0.60, 95% confidence interval = 0.12 to 3.13; number needed to treat to prevent one additional DFS event at 5 years: 10 and 11.2 patients, respectively). Following the 2007 ASCO/CAP criteria for HER2 positivity would negate the option of potentially life-saving trastuzumab therapy for a small but meaningful group of patients. We recommend using FDA-approved HER2 criteria for therapeutic decision making.

AB - The 2007 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity of tumors that modified those of the US Food and Drug Administration (FDA), causing some confusion and uncertainty among clinicians. Using data from the HER2-positive breast cancer adjuvant trial N9831, we compared eligibility for patients who met both criteria, and disease-free survival (DFS) was assessed by Cox proportional hazards regression. The number of patients in the N9831 trial retrospectively eligible for trastuzumab therapy was decreased when ASCO/CAP criteria vs FDA criteria were applied to immunohistochemistry and/or fluorescence in situ hybridization results (107 [3.7%] of 2904 patients with immunohistochemistry results, 37 [1.3%] of 2809 patients with fluorescence in situ hybridization results, and 47 [1.7%] of 2809 patients with both results). Improvement in DFS was similar among patients treated with trastuzumab under either set of criteria (concurrent trastuzumab and chemotherapy compared with chemotherapy alone: by ASCO/CAP criteria, hazard ratio of DFS = 0.59, 95% confidence interval = 0.48 to 0.73; by FDA criteria but not ASCO/CAP criteria, hazard ratio = 0.60, 95% confidence interval = 0.12 to 3.13; number needed to treat to prevent one additional DFS event at 5 years: 10 and 11.2 patients, respectively). Following the 2007 ASCO/CAP criteria for HER2 positivity would negate the option of potentially life-saving trastuzumab therapy for a small but meaningful group of patients. We recommend using FDA-approved HER2 criteria for therapeutic decision making.

UR - http://www.scopus.com/inward/record.url?scp=84862908745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862908745&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr490

DO - 10.1093/jnci/djr490

M3 - Article

VL - 104

SP - 159

EP - 162

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -